Hepatocellular Cancer Clinical Trial
Official title:
A Single-center, Prospective Randomized Controlled Study of Microwave Spherical Ablation and Traditional Microwave Ablation in the Treatment of Single Hepatocellular Carcinoma With a Diameter of ≤5cm
Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm.
HCC is a serious threat to the health of people，Early treatment of HCC results in a good prognosis for patients. Microwave ablation (MWA) is an important method for the treatment of early HCC. The traditional MWA technology has a long diameter of the ablation foci which is much larger than the transverse diameter, so in order to obtain a sufficient transverse diameter, the long diameter is often too large beyond the tumor boundary. That will cause too much normal liver tissue is unnecessarily damaged, especially for patients with severe liver cirrhosis or patients with liver cirrhosis who have undergone liver resection. In addition, it is easy to cause damage to adjacent vital tissues and organs. Changes in tissue properties during ablation affect the stability of the microwave field, resulting in unpredictable ablation shapes, which may cause omissions during tumor ablation, especially in multiple overlapping ablation, resulting in incomplete ablation, or increasing the risk of local tumor progression after treatment. Microwave spherical ablation (MSA) technology is a new MWA technology. With the help of temperature control technology, field control technology and wave control technology, a single needle can produce predictable spherical ablation lesions. Theoretically, MSA can improve the controllability of the ablation foci, which is suitable for the purpose of conformal ablation of large tumors in clinical practice, thereby minimizing the damage of local thermal ablation to liver tissue and adjacent important organs. However, there are few reports on the comparison of the therapeutic effect of MSA and traditional MWA. This study intends to conduct a prospective randomized controlled study based on the two mature microwave treatment methods of MSA and traditional MWA ablation to explore the effectiveness and safety of MSA in clinical application, providing evidence-based medical evidence for the clinical application of MSA. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
| Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
| Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
| Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
| Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
| Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
| Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
| Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
| Suspended |
NCT00909558 -
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
|
Phase 1 |